Novartis Upbeat As Ofatumumab Data Delivers In MS

Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.

Home_Shelf
If approved, ofatumumab could be self-administered at home • Source: Shutterstock

Novartis AG has presented detailed data on its latest multiple sclerosis drug ofatumumab which the company believes will provide a more convenient treatment for patients than Roche's rival therapy Ocrevus.

Having published positive topline results last month, Novartis presented the full data set from the Phase III ASCLEPIOS I and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category